- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 817KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 41KB)
Cabazitaxel – March 2021
Cabazitaxel: Concentrated injection 60 mg (as acetone solvate) in 1.5 mL, with diluent; Cabazitaxel Ever Pharma®
Last updated
2 July 2021